• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by MeiraGTx Holdings plc

    10/18/24 4:47:58 PM ET
    $MGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MGTX alert in real time by email
    SC 13G/A 1 s13g_101524-meiragtx.htm SCHEDULE 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 2)1
     
     
    MeiraGTx Holdings plc
    (Name of Issuer)
     
     
    Ordinary Shares, $.00003881 par value
    (Title of Class of Securities)
     
    G59665102
    (CUSIP Number)
     
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [ ] Rule 13d-1(d)

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     
     

     

    CUSIP No. G59665102 Page 2

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 6,641,064
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 6,641,064
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,641,064
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.6%
    12. TYPE OF REPORTING PERSON CO
             

     

     

     

     
     

     

    CUSIP No. G59665102 Page 3

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson Innovation-JJDC, Inc.

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 6,641,064
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 6,641,064
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 6,641,064
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.6%
    12. TYPE OF REPORTING PERSON CO
             

     

     

     
     

     

    CUSIP No. G59665102 Page 4

     

     

    AMENDMENT NO. 2 TO SCHEDULE 13G

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Ordinary Shares of the Issuer on March 4, 2019 and Amendment No. 1 thereto on November 14, 2022 (as so amended, the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following items of the Schedule 13G are amended and restated to read in their entirety as follows:

     

    Item 2(a). Name of Person Filing

     

    This statement is being filed by Johnson & Johnson, a New Jersey corporation (“J&J”), and Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”) (together, the Reporting Persons”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by J&J and JJDC are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between the Reporting Persons was filed as Exhibit 1 to the Schedule 13G.

     

    Item 2(a). Citizenship

     

    J&J: New Jersey

    JJDC: Delaware

     

    Item 4. Ownership

    The information requested in this item is incorporated herein by reference to the cover pages to this Amendment No. 2 to Schedule 13G. Ownership percentage is based on 77,184,187 Ordinary Shares outstanding as of August 13, 2024, as reported in the Issuer’s Prospectus on Form 424B5 filed with the Securities and Exchange Commission on of August 12, 2024 relating to an offering of Ordinary Shares that closed on August 13, 2024.

     

     
     

     

    CUSIP No. G59665102 Page 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 18, 2024

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         
         
      JOHNSON & JOHNSON INNOVATION-JJDC, INC.
         
      By: /s/ Jill McManus
      Name: Jill McManus
      Title: Assistant Treasurer

     

     

     

    Get the next $MGTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTX

    DatePrice TargetRatingAnalyst
    7/31/2024$36.00Buy
    Chardan Capital Markets
    More analyst ratings